Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Granted Two New US Patents

Drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) this morning announced that it has been granted two new U.S. patents. Per the update, the two new patents are related to certain cannabinoid infused beverage compositions utilizing Lexaria’s proprietary DehydraTECH process, a process which continues to strengthen the company’s dominant intellectual property position in the growing cannabis beverage market. With these new additions, Lexaria now has six granted patents in the U.S. and four granted patents in Australia, all 10 of which fall within the company’s first patent family, “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof.” Lexaria is currently pursuing accelerated examination for patent applications in Australia based on these newest U.S. patents and hopes to receive two corresponding Australian patents by the end of 2018.

To view the full press release, visit https://cnw.fm/mSU72

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. licenses disruptive patented delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com